Sector News

Eli Lilly pours $500M more into API manufacturing site under construction in Ireland

March 31, 2023
Life sciences

Eli Lilly is literally doubling down on its biologics manufacturing facility under construction in Ireland.

The company plans to pour more than $500 million in additional funds into its active pharmaceutical ingredient (API) plant in Raheen, Limerick County, the country’s Industrial Development Agency (IDA) said. The new funding brings the company’s total investment in the site to 927 million euros ($1 billion).

Lilly confirmed the dollar figures but did not say how many more people the site will eventually employ. When plans for the site were revealed, in January of last year, the company said it would house 300 engineering, scientific and operations personnel.

The company said that 1,200 people will now be engaged in construction of the Raheen site.

Lilly CEO David Ricks attended a ceremony where officials announced the deal, The Irish Times reports. The company offered few details about its planned operations there, saying in a statement the plant would “expand Lilly’s manufacturing network for biologic active ingredients.”

When the company originally announced its plan for the site, it cited “increased demand for existing Lilly products,” and added that it would “play a key role” in the manufacture of Lilly’s clinical pipeline products “including its promising Alzheimer’s portfolio.”

Two months ago, the FDA sent Lilly a complete response letter for its application for approval of Alzheimer’s candidate donanemab.

Meanwhile, Lilly has been scaling up efforts to meet increased demand for its diabetes products, including Mounjaro.

The company also is building a $1.7 billion manufacturing site in Concord, North Carolina, which will employ more than 700.

Lilly is among several pharmaceutical companies that have established a manufacturing footprint in business-friendly Ireland. Lilly already employs 2,700 in County Cork at its Kinsale and Little Island sites. Lilly’s presence in the country dates to 1978.

By Kevin Dunleavy

Source: fiercepharma.com

comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach